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comparison with normal skin. The role
of Th2 cytokines was then confirmed
using keratinocyte primary cultures trea-
ted with IL-4/IL-13. In contrast, gamma-
INF treatment did not modulate alpha
toxin–mediated cytotoxicity. IL-4/IL-13
augmentation of alpha toxin–mediated
cytotoxicity was shown to be due to the
ability of these Th2 cytokines to
decrease the levels of acid sphingo-
myelinase, the enzyme that cleaves
sphingomyelin into ceramide and phos-
phocholine. The ability of exogenous
sphingomyelinase or phosphocholine
to reverse the alpha toxin toxicity not
only confirmed the mechanisms but also
provided the rationale for possible
therapeutics.
The authors also demonstrated in a
recent companion report that the epider-
mal barrier protein filaggrin also has an
important role in the regulation of acid
sphingomyelinase, and that deficiency in
filaggrin predisposes for increased alpha
toxin–mediated cytotoxicity (Brauweiler
et al., 2013). Relevant to Th2 cytokines,
IL-4 and IL-13 have also been shown to
inhibit filaggrin expression (Howell
et al., 2009). Thus, one can envision a
positive feedback pathway by which
Th2 cytokines not only provide a permis-
sive environment for S. aureus but also
enhance the effects of staphylococcal
products. These findings are compatible
with the notion that strategies that
remove bacteria, such as dilute bleach
baths, can improve AD skin disease
(Huang et al., 2009).
In summary, the interplay between
Th2 cytokines and S. aureus has high
significance for understanding AD.
Indeed, the majority of AD flares
involve S. aureus in some capacity.
New insights into the exact mechanisms
by which staphylococcal exposure can
worsen AD could allow improved and
novel treatments for this common skin
disease and its significant morbidities.
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A Possible Role for IL-17A in
Establishing Th2 Inflammation in
Murine Models of Atopic Dermatitis
Nikhil Dhingra1,2 and Emma Guttman-Yassky1,3
Atopic dermatitis (AD) is associated with the effects of T helper type 2 (Th2) and
Th22 cytokines. Recent studies, however, have also implicated Th17 in acute AD.
Functional studies of Th2 and Th22 cytokines revealed their roles in generating
molecular changes during AD; IL-17A’s role, however, has yet to be defined. The
report by Nakajima et al. (this issue) begins to define that role by demonstrating
IL-17A’s ability to induce Th2 inflammation in acute disease.
Journal of Investigative Dermatology (2014) 134, 2071–2074. doi:10.1038/jid.2014.141
Atopic dermatitis (AD) is a chronic
inflammatory skin disease characterized
by acute and chronic stages. The patho-
genesis of AD is still unclear; both
immune- and barrier-driven mechan-
isms have been demonstrated in murine
models and in human disease. AD has
been recognized predominantly as a
T helper type 2 (Th2)/Th22-centered
disease (Guttman-Yassky et al., 2011).
Lesional AD skin is characterized pri-
marily by increased expression of Th2
cytokines and chemokines (IL-4/IL-13,
chemokine (C-C motif) ligand (CCL)17,
OX40), Th22-related markers (IL-22), as
well as Th1- (chemokine (CXC motif)
ligand (CXCL10)), Th17- (Elafin/PI3,
CXCL1), and Th17/Th22-mediated S100
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epidermal responses. Although the
pathogenic role of Th17 in psoriasis is
well established and supported by disease
antagonism with anti-IL-17 biologics (i.e.,
brodalumab, ixekizumab, and secuki-
numab), its role in the pathogenesis of
AD remains unclear. Although IL-17 is
increased in skin and peripheral blood in
patients with acute disease (Gittler et al.,
2012), IL-17 and its associated antimicro-
bial peptides are much lower than in
psoriasis, possibly explaining the increa-
sed risk of infections in AD (reviewed in
Guttman-Yassky et al., 2011). A recent
study by our group compared non-
lesional tissue with that of acute and
chronic lesions from the same patient,
which revealed increased expression of
IL-17 and several associated markers
(CCL20, PI3) in acute AD compared
with non-lesional skin. Interestingly,
levels remained insignificantly changed
as disease progressed to the chronic
stage (Gittler et al., 2012; Figure 1).
Obtaining a functional understanding for
IL-17A in AD has remained elusive until
now. In this issue, Nakajima et al.,
(2014) used two murine models of AD,
including hapten-mediated induction
and flaky-tailed mice with spontaneous
lesions, in the setting of IL-17A defici-
ency to evaluate its role in disease patho-
genesis.
Th2 induction by IL-17A in a murine
model of AD-like inflammation
Using both models, Nakajima et al.
(2014) demonstrated that IL-17A defi-
ciency attenuated Th2 induction during
the acute phase of inflammation, implicat-
ing IL-17A as an inducer or modifier that
drives IL-17A T cells toward Th2 in the
early inflammation of susceptible skin.
The hapten-induced mouse model of AD
relies on the concept that chronic hapten
exposure across an impaired barrier esta-
blishes a pro-inflammatory milieu (the
‘‘hapten-atopy hypothesis’’; McFadden
et al., 2011) dominated by Th2 T cells,
mimicking the inflammation in AD skin.
The hapten model by Nakajima et al.
(2014) may explain how an immune
response to an external allergic agent, via
IL-17A-mediated Th2 induction, ultima-
tely polarizes toward the acute AD
cytokine milieu that has been described
previously. In addition, the demonstration
by Nakajima et al. (2014) of similar
immune findings in barrier-deficient
mice with spontaneous AD-like lesions
helps to bridge our understanding of why
some patients develop lesions only in the
setting of a sensitizer, whereas others
develop them spontaneously. Their
finding that contact allergen-triggered
disease and barrier deficiency both result
in similar IL-17A-mediated induction of
Th2 inflammation may explain how this
clinical phenomenon occurs.
Interestingly, in a recent report,
Newell et al. (2013) described the use
of the potent hapten dinitrochloro-
benzene to study contact sensitization
in humans, revealing an interesting
dichotomy between patients with AD
and volunteers without AD. Those with
a history of AD exhibited preferential
Th2 induction, whereas those without
AD exhibited a Th1 response primarily.
Thus, it can be postulated that in human
AD, an allergen penetrating across a
defective barrier may trigger low-grade
IL-17A release; with ongoing stimulation
by chronic happen exposure, it may
induce Th2-polarizing molecules (thymic
stromal lymphopoietin, CCL17), pro-
moting naı¨ve T cells toward Th2 and
establishing the predominant immune
polarization of AD. Interestingly, a
similar concept may be applied to the
role of Staphyloccoccus aureus, another
implicated extrinsic agent, in triggering
AD exacerbations. S. aureus superan-
tigens, like the haptens in the study by
Nakajima et al. (2014), were also
demonstrated to induce IL-17A expres-
sion (Boguniewicz and Leung, 2010),
potentially suggesting a common molec-
ular link between the two major
external inducers of disease flares.
Limitations of the murine contact
hypersensitivity model and our current
understanding of IL-17 signaling
introduce new questions
The AD mouse models used by Nakajima
et al. (2014) have several inherent limita-
tions with respect to their translatability to
humans. Specifically, at present, no single
mouse model represents acute and
chronic AD with true accuracy; rather,
these models are able to represent select
characteristics of the disease process and
generate AD-like clinical and molecular
inflammation. The murine contact hyper-
sensitivity model, for instance, can only
be induced via potent sensitizing agents
such as dinitrochlorobenzene, which
have an inherent irritating capacity and
thus induce nonspecific immune activa-
tion (i.e., of the innate immune response)
in addition to antigen-specific activation.
Conversely, clinically relevant sensitizers
that cause allergic contact dermatitis, and
may trigger human AD, do not exhibit an
initial irritant response, thus making it
difficult to translate the generated immu-
nological data fully to human models.
Another important limitation relates to gd
T cells, which Nakajima et al. (2014)
found to be the chief producers of IL-17A
in their study; the role of these T cells in
human IL-17 production is unknown at
present, and thus it is unclear whether a
similar mechanism may exist in humans.
Only a few studies prior to those by
Nakajima et al. (2014) evaluated the
human effector interplay between IL-
17A and the Th2 pathway, particularly
in skin disease, and a select subset
from other tissue types reported results
contradictory to those in this study. One
such work, by Xu et al. (2010), on
cultured nasal epithelial cells revealed
an inhibitory effect of IL-17A on thymic
stromal lymphopoietin expression,
whereas Th2-sourced IL-25 (also known
as IL-17E) had the opposite effect.
Studies in skin too have produced dissi-
milar results from those by Nakajima
Clinical Implications
 Nakajima et al. (2014) demonstrated IL-17A-mediated induction of Th2 inflam-
mation in the setting of hapten exposure or barrier disruption in murine
models, thereby introducing a new facet into AD pathogenesis models.
 Their finding provides a better understanding of the primary immuno-
logical processes that initiate acute and chronic disease.
 Ongoing studies in humans using IL-4- and IL-17-targeted biologics will
provide additional insights into the translatability of this finding.
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et al. (2014). Bogiatzi et al. (2012)
demonstrated, using human skin
explants and cultured dendritic cells,
that IL-17A induced marked decreases
in thymic stromal lymphopoietin and
Th2-related cytokine production. Eyerich
et al. (2009) complicated this picture
further, postulating that IL-4 was capable
of inhibiting the IL-17 pathway as well.
A final point of consideration is revea-
led in recent studies that identified a
subset of Th2 T cells capable of producing
IL-17A itself. Wang et al. (2010) demon-
strated the presence of these IL-4- and
IL-17-producing Th2 T cells in peripheral
blood of allergic asthmatics. It can be
postulated that IL-17A produced by these
dual-function cells may signal back on
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Figure 1. A schematic illustration of the initiation of acute atopic dermatitis (AD) and progression to chronic skin lesions. Non-lesional AD skin lesions show
some immune infiltrates that produce inflammatory mediators, which may contribute to a defective epidermal barrier. Barrier defects lead to penetration by
epicutaneous antigens that encounter Langerhans cells in the epidermis and dermal dendritic cells (DCs) in the dermis, inducing marked immune activation and
recruitment of inflammatory cells in acute AD lesions. The finding by Nakajima et al. (2014) regarding the role of IL-17A may potentially bridge the gap between
non-lesional skin following antigen penetration and onset of acute disease, where T helper type 17 (Th17) T cells have been identified in limited quantities. This
relatively small Th17 activity could potentially lead to the marked activation of Th2 axis in acute disease onset; Th22 activity also increases. A progressive
activation of the Th2, Th22, and Th1 pathways is characteristic of the chronic stage of AD; Th17 activity remains constant from acute disease. Cytokines (i.e., IL-4
and IL-13) and chemokines (i.e., chemokine (C-C motif) ligand (CCL)17, CCL18, CCL19, chemokine (CXC motif) ligand (CXCL)9, CXCL10, and CXCL11) produced
by various T cells and DCs induce further activation and recruitment of additional immune cells. With the onset of acute disease, Th22 cells release IL-22, which
induces epidermal hyperplasia and, synergistically with the Th17 cytokine IL-17, drives an abrupt increase in a subset of terminal differentiation genes, specifically
the S100A7, S100A8, and S100A9 proteins. The increases in these barrier proteins contrast with the uniformly disrupted epidermal differentiation gene products
(e.g., filaggrin, loricrin, and corneodesmosin) throughout non-lesional, acute, and chronic AD skin. The Th2 and Th22 cytokines contribute to inhibition of the
terminal differentiation proteins. IL-31 is abruptly upregulated in acute disease, potentially reflecting its role as an itch mediator in patients with AD. Figure and
legend adapted and modified from Gittler et al. (2012) with permission from Elsevier/RightsLink.
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naive T cells, augmenting Th2 activity.
Interestingly, they reported that these cells
could be stimulated to produce IL-17 by
IL-1b, IL-6, and IL-21 but not by IL-23,
suggesting a distinct mechanism from
classical Th17-mediated release. The
same study found that in murine models
of allergic asthma, mice with allergen-
specific IL-17-producing Th2 cells exhibi-
ted increased airway inflammation
following allergen exposure, suggesting
some correlation between clinical
disease activity and stimulation of these
IL-17-producing Th2 T cells. Similarly, in
skin, Eyerich et al. (2009) used eczema
samples and identified that approximately
one-third of IL-17-producing cells exhi-
bited a concurrent Th0 or Th2 profile
(both IL-4-producing without or with
IFN-g, respectively). Thus, additional
studies, based on the work by Nakajima
et al. (2014), will be required to evaluate
the possibility that IL-17A is itself being
sourced from a subset of Th2 T cells
rather than from the classically pre-
sumed Th17 cells.
Upcoming targeted therapeutics for AD
may reveal further insights into the role of
cytokine interplay in disease pathogenesis
AD research has recently entered a new
era in which our collective understand-
ing of the immune mechanisms driving
disease has led to the development and
testing of agents targeting key molecules
in pathogenic pathways. A clinical trial
that is currently being conducted by
our group testing ustekinumab (anti-IL-
23p40) (clinicaltrials.gov, NCT01806662)
in AD patients may help elucidate the
effects of IL-17A inhibition on Th2
cytokine induction. By inhibiting Th17
T-cell activation (and thus significant
IL-17 production) with this biologic, we
will be able to evaluate the posttreat-
ment effects of such a blockade on all
the major inflammatory axes, including
Th2 T cells and their associated markers.
In doing so, our study may bridge the
murine work by Nakajima et al. (2014)
to humans, potentially providing insights
into whether IL-17 inhibition truly
reduces Th2 activity. Conversely, dupilu-
mab (clinicaltrials.gov, NCT01859988), a
mAb that inhibits IL-4Ra, dually block-
ing IL-4 and IL-13 signaling may shed
light on the effects of Th2 inhibition on
the IL-17 pathway genes in addition to
the other major T-cell axes. Moving
forward, a bedside-to-bench approach
with pathway-targeted therapeutics will
enable us to not only test the efficacies
of these drugs but also potentially unveil
additional novel targets in the major
inflammatory pathways. The work by
Nakajima et al. (2014) in this issue of
the journal, however, presents a fasci-
nating model for the initiation of Th2
inflammation in AD, providing a poten-
tial therapeutic target and an exciting
clue into the early stages of the slowly
unraveling AD pathogenesis model.
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Oxidative Stress and Vitiligo: The
Nrf2–ARE Signaling Connection
Lei Qiu1, Zhiqi Song1 and Vijayasaradhi Setaluri2
Hypersensitivity of epidermal melanocytes to oxidative stress is known to contribute
to vitiligo pathogenesis. Molecular mechanisms that connect melanocyte redox
homeostasis to the complex disease phenotype are not fully understood. Jian et al.
show that vitiligo melanocytes have impaired nuclear factor erythroid 2–related
factor 2 (Nrf2)–antioxidant response element signaling and decreased activation of
the antioxidant enzyme system. In patients with vitiligo, higher serum levels of IL-2
correlate with lower levels of hemeoxygenase-1, a product of the Nrf2 target gene.
Journal of Investigative Dermatology (2014) 134, 2074–2076. doi:10.1038/jid.2014.241
Degeneration of melanocytes, the cel-
lular source of melanin pigment, is the
pathologic hallmark of depigmented
macules in patients with vitiligo. Viti-
ligo is now recognized as a disorder of
multifactorial etiology culminating in
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